11 active not recruiting, 9 completed, 6 terminated, 4 recruiting. 16 Phase 2, 13 Phase 3, 7 Phase 1.
By phase and status
Follow ianalumab: new trials by email Literature Review of ianalumab trials Research Report on ianalumab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix .
Trial Phase Status Sponsor Enrollment Start Updated
A Study of Ianalumab in Addition to Eltrombopag in Pediatric Patients With Primary ITP Who Failed Corticosteroids. Ianalumab, Eltrombopag - Primary Immune Thrombocytopenia (ITP) Phase 2 Not yet recruiting 36 2027-02-08 2026-06-25
A Study to Assess the Tolerability of Ianalumab (VAY736) With Investigator's Choice Thrombopoietin Receptor Agonist (IC TPO-RA) in Patients With Primary Immune Thrombocytopenia (ITP) ianalumab, thrombopoietin receptor agonist (TPO-RA) - Primary Immune Thrombocytopenia (ITP), Primary Evans Syndrome (ES) Phase 2 Recruiting 164 2026-08-04 2026-11-17
Two Arm, Double-blind, Phase III Study Assessing Efficacy and Safety of Ianalumab Versus Placebo, in Participants With Sjögren's Disease With High Symptom Burden VAY736, Placebo - Sjögren´s Disease Phase 3 Recruiting 570 2026-07-16 2026-11-09
Study of Ianalumab in Adults With Primary Immune Thrombocytopenia (ITP) and Warm-antibody Autoimmune Hemolytic Anemia (wAIHA) Who Have Previously Benefited From Ianalumab Ianalumab - Primary Immune Thrombocytopenia, Warm Autoimmune Hemolytic Anemia Phase 2 Withdrawn 2026-06-26 2026-10-15
Phase III Extension Study of Efficacy and Safety of Ianalumab With or Without Study Treatment Withdrawal in Participants With Lupus Nephritis (SIRIUS-LN Extension) Ianalumab - Lupus Nephritis Phase 3 Recruiting 348 2025-05-19 2026-11-09
Pharmacokinetics Study of Ianalumab in Chinese Participants With Autoimmune Diseases ianalumab - Sjogren Disease, Systemic Lupus Erythematosus Phase 1 Withdrawn 2024-11-25 2025-01-27
A Clinical Study to Evaluate Ianalumab in Participants With Diffuse Cutaneous Systemic Sclerosis Placebo, Ianalumab - Diffuse Cutaneous Systemic Sclerosis Phase 2 Active not recruiting 203 2024-10-09 2026-11-09
Two-period Crossover Study to Demonstrate the Comparability of Pharmacokinetics of Subcutaneous Ianalumab Between 2mL Auto-injector/2mL PFS with1mL Pre-filled Syringe in Adult Participants With Autoimmune Disease VAY736 1ml PFS, VAY736 2 ml PFS, VAY736 2ml AI - Sjögrens Disease, Systemic Lupus Erythematosus Phase 2 Active not recruiting 155 2024-07-02 2026-10-14
Phase 3 Extension Study to Evaluate Long-term Safety of Ianalumab in Participants With Systemic Lupus Erythematosus (SIRIUS-SLE Extension). Placebo, Ianalumab - Systemic Lupus Erythematosus Phase 3 Recruiting 550 2024-05-21 2026-11-09
A Randomized, Double-blind 2-arm, Followed by an Open-label 1-arm, NEPTUNUS Extension Study to Assess the Long-term Safety and Efficacy of Ianalumab in Patients With Sjogrens Syndrome. Ianalumab (VAY736), Placebo - Sjogrens Syndrome Phase 3 Active not recruiting 612 2023-10-27 2026-10-15
A Study of Ianalumab (VAY736) in Patients With Primary Immune Thrombocytopenia (ITP) Previously Treated With at Least Two Lines of Therapies Ianalumab - Primary Immune Thrombocytopenia (ITP) Phase 2 Active not recruiting 41 2023-08-16 2026-10-20
Phase 3 Study to Evaluate Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 2) ianalumab, placebo - Systemic Lupus Erythematosus Phase 3 Active not recruiting 288 2023-04-21 2026-10-14
Phase 3 Study to Evaluate Two Regimens of Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 1) Ianalumab, Placebo - Systemic Lupus Erythematosus Phase 3 Active not recruiting 436 2023-03-02 2026-10-14
Study of Ianalumab Versus Placebo in Addition to First-line Corticosteroids in Primary Immune Thrombocytopenia (ITP) Ianalumab, Placebo, Corticosteroids - Primary Immune Thrombocytopenia (ITP) Phase 3 Active not recruiting 226 2023-02-03 2026-11-12
A Study of Efficacy and Safety of Ianalumab Versus Placebo in Addition to Eltrombopag in Primary Immune Thrombocytopenia Patients Who Failed Steroids Ianalumab, Eltrombopag, Placebo - Primary Immune Thrombocytopenia Phase 3 Active not recruiting 152 2023-02-02 2026-11-09
A Study of Efficacy and Safety of Ianalumab in Previously Treated Patients With Warm Autoimmune Hemolytic Anemia Ianalumab, Placebo - Warm Autoimmune Hemolytic Anemia (wAIHA) Phase 3 Active not recruiting 90 2022-12-30 2026-09-11
Three-arm Study to Assess Efficacy and Safety of Ianalumab (VAY736) in Patients With Active Sjogren's Syndrome VAY736, Placebo - Sjogren Syndrome Phase 3 Active not recruiting 506 2022-08-04 2026-06-17
Two-arm Study to Assess Efficacy and Safety of Ianalumab (VAY736) in Patients With Active Sjogren's Syndrome VAY736, Placebo - Sjogren Syndrome Phase 3 Completed 275 2022-07-28 2026-07-07
Biopsy Based Study to Understand Mechanism of Action of Ianalumab in Salivary Glands and Explore Relationships With Clinical Assessments. Ianalumab - Sjogren Syndrome Phase 2 Completed 21 2022-07-27 2026-02-02
Safety, Efficacy and Tolerability of Ianalumab Versus Placebo, Combination With SoC Therapy, in Participants With Active Lupus Nephritis ianalumab s.c. q4w, ianalumab s.c. q12w, placebo s.c. - Lupus Nephritis Phase 3 Active not recruiting 452 2022-07-14 2026-10-15
Showing 20 of 35. Sign in to see all of them.
Conditions studied Lupus Erythematosus, Systemic (7) · Purpura, Thrombocytopenic, Idiopathic (7) · Sjogren's Syndrome (7) · Arthritis, Rheumatoid (3) · Leukemia, Lymphocytic, Chronic, B-Cell (2) · Lupus Nephritis (2) · Autoimmune Diseases (1) · Dry Eye Syndromes (1) · Evans Syndrome (1) · Fatigue (1) · Hepatitis, Autoimmune (1) · Hidradenitis Suppurativa (1) · Idiopathic Pulmonary Fibrosis (1) · Lymphoma, B-Cell, Marginal Zone (1) · Lymphoma, Follicular (1)
Sponsors Novartis Pharmaceuticals (35)
Countries United States (24) · Germany (21) · Spain (19) · France (17) · Argentina (15) · China (15) · Hungary (15) · Czechia (14) · Italy (14) · United Kingdom (13) · Japan (12) · South Korea (12) · Taiwan (12) · Australia (10) · India (10)
Results publications PMID 34398557 , PMID 34861168 , PMID 35179437 , PMID 37722131 , PMID 39557617 , PMID 40465397 , PMID 41217519 , PMID 41363800
NIH funding 2023 (7) , 2018 (2) , 2017 (1) , 2025 (1) , R01CA177292 (1)